<DOC>
	<DOCNO>NCT00002746</DOCNO>
	<brief_summary>RATIONALE : Interleukin-2 may stimulate person 's white blood cell kill cancer cell . PURPOSE : Phase I trial study effectiveness interleukin-2 treating patient myelodysplastic syndrome .</brief_summary>
	<brief_title>Interleukin-2 Treating Patients With Myelodysplastic Syndrome</brief_title>
	<detailed_description>OBJECTIVES : - Determine safety , tolerance , maximum tolerate dose subcutaneous interleukin-2 ( aldesleukin ; IL-2 ) patient myelodysplastic syndrome ( MDS ) . - Evaluate hematologic effect subcutaneous IL-2 MDS . OUTLINE : IL-2 administered cycle twice daily subcutaneous injection 7 day week 4 consecutive week . After cycle patient evaluate response . The patient could continue IL-2 therapy 12 cycle . There 4 dose level IL-2 . At dose level 3 patient accrue sequentially . Treatment IL-2 continue grade III toxicity side effect require hospitalization occurs . After patient return baseline pretherapy value grade I toxicity , subject resume IL-2 50 % initial dose . If patient go grade III toxicity need hospitalization , IL-2 discontinue . PROJECTED ACCRUAL : Between 12-24 patient accrue .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Myelodysplastic-Myeloproliferative Diseases</mesh_term>
	<mesh_term>Aldesleukin</mesh_term>
	<mesh_term>Interleukin-2</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm myelodysplastic syndrome : Refractory anemia ( RA ) , refractory anemia ring sideroblast ( RARS ) , refractory anemia excess blast ( RAEB ) chronic myelomonocytic leukemia ( CMML ) No patient refractory anemia excess blast transformation ( RAEBt ) PATIENT CHARACTERISTICS : Age : 15 Performance status : Karnofsky 70100 Hematopoietic : Platelet count great 20,000 Hepatic : Bilirubin le 1.6 mg/dL SGOT le 150 U/L Renal : Creatinine great 2.0 mg/dL Cardiovascular : No symptom coronary artery disease , congestive heart failure , edema , clinically manifest hypotension , presence cardiac arrhythmia EKG , severe hypertension Pulmonary : No significant pleural effusion , dyspnea rest severe exertional dyspnea Other : No patient nephrotic syndrome No uncontrolled infection active peptic ulcer disease No serious intercurrent medical illness Not pregnant nursing Adequate contraception require patient PRIOR CONCURRENT THERAPY : Biologic therapy : At least 4 week since prior immunosuppressive therapy Chemotherapy : At least 4 week since prior chemotherapy Endocrine therapy : At least 2 week since corticosteroid therapy At least 4 week since endocrine therapy Radiotherapy : At least 4 week since prior radiotherapy Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>refractory anemia</keyword>
	<keyword>refractory anemia ring sideroblast</keyword>
	<keyword>refractory anemia excess blast</keyword>
	<keyword>chronic myelomonocytic leukemia</keyword>
	<keyword>de novo myelodysplastic syndrome</keyword>
	<keyword>previously treat myelodysplastic syndrome</keyword>
	<keyword>secondary myelodysplastic syndrome</keyword>
	<keyword>atypical chronic myeloid leukemia , BCR-ABL1 negative</keyword>
	<keyword>myelodysplastic/myeloproliferative neoplasm , unclassifiable</keyword>
	<keyword>childhood myelodysplastic syndrome</keyword>
</DOC>